- StemCells (STEM +1.4%) announces the enrollment its first patient in Cohort 2 of its Phase 2 Pathway Study, designed to assess the efficacy of its HuCNS-SC (purified human neural stem cells) for the treatment of cervical spinal cord injury. Cohort 2 will enroll 40 patients and will constitute the single-blind control arm. The primary endpoint is the change in motor strength from baseline in the upper extremities.
- The Pathway Study has three cohorts: Cohort 1 is a dose-escalation arm involving six patients, Cohort 2 will assess efficacy in 40 patients and Cohort 3 is an optional open label arm involving six patients with less severe injuries. The trial will follow the participants for one year. Enrollment in Cohort 1 was completed in April.